Biologic therapies targeting TNF-α administered intravenously or subcutaneously have transformed the treatment of IBD and emerged as the most effective agents for achieving and maintaining disease remission (Souza et al., 2023). The gene discussed is TNF; the disease is inflammatory bowel disease.